5α-Reductase Inhibitors (Finasteride, Dutasteride)
5α-Reductase inhibitors (finasteride, dutasteride) block the enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent androgen responsible for prostate growth and male-pattern hair loss, and USMLE Step 1 tests this drug class at the mechanism level and at the clinical application level. These drugs treat BPH and androgenetic alopecia by starving androgen-sensitive tissue of DHT while leaving circulating testosterone largely intact. The exam specifically distinguishes enzyme inhibition from receptor blockade, and covers PSA interpretation and teratogenicity precautions.
The exam loves to drop finasteride into a vignette about BPH management or prostate cancer screening and then ask you to interpret a lab value or make a clinical decision. The tricky part isn't knowing what finasteride does in isolation — it's applying that knowledge when a patient's PSA comes back 'normal' and you have to recognize that the number is artifactually suppressed. Finasteride roughly halves serum PSA, so a measured value of 2 ng/mL should be read as ~4 ng/mL for screening purposes. Missing this correction is one of the most commonly tested gaps on Step 1 for this drug.
A second high-yield angle is teratogenicity. Finasteride is teratogenic to male fetuses because DHT is required for normal virilization of external genitalia. The exam tests whether you know that even pregnant women handling crushed or broken tablets face risk from transdermal absorption — not just patients taking the drug orally. These two angles (PSA correction and teratogenic precautions) are where most students lose points, not on the basic mechanism.
A gap in most decks — fewer than half of students in our cohort have cards covering this topic.
Common misconceptions
What the exam tests
- Understand the mechanism of 5α-reductase inhibitors: they prevent conversion of testosterone to DHT at the enzyme level, which is distinct from androgen receptor blockers like flutamide that work downstream at the receptor.
- Know how finasteride affects PSA interpretation: because it suppresses PSA by approximately 50%, a measured PSA on a patient taking finasteride must be doubled to estimate the true baseline value for prostate cancer screening purposes.
- Recognize the teratogenic risk of finasteride to male fetuses and understand that pregnant women must not handle crushed or broken tablets due to the risk of transdermal absorption causing impaired virilization.
Can you avoid these mistakes?
Related topics
See how your Anki deck covers this topic.
Upload your deck for a free audit →